Regenicin Valuation
| RGIN Stock | USD 0.0001 0.00 0.00% |
Regenicin seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Regenicin from analyzing the company fundamentals such as Shares Owned By Insiders of 18.15 %, net income of (639.26 K), and Return On Asset of -37.38 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Regenicin's price fluctuation is very steady at this time. Calculation of the real value of Regenicin is based on 3 months time horizon. Increasing Regenicin's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Regenicin is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regenicin Pink Sheet. However, Regenicin's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Regenicin's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regenicin's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regenicin helps investors to forecast how Regenicin pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regenicin more accurately as focusing exclusively on Regenicin's fundamentals will not take into account other important factors: Regenicin Total Value Analysis
Regenicin is at this time forecasted to have valuation of 659.26 K with market capitalization of 214.88 K, debt of 629.92 K, and cash on hands of 2.24 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Regenicin fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
659.26 K | 214.88 K | 629.92 K | 2.24 K |
Regenicin Asset Utilization
One of the ways to look at asset utilization of Regenicin is to check how much profit was generated for every dollar of assets it reports. Regenicin holds a negative application of assets of -37.38 pct., losing $0.37 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Regenicin shows how discouraging it operates for each dollar spent on its assets.Regenicin Ownership Allocation
Regenicin owns a total of 153.48 Million outstanding shares. Regenicin holds 18.15 pct. of its outstanding shares held by insiders and 0.018 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Regenicin Profitability Analysis
Net Loss for the year was (639.26 K) with profit before overhead, payroll, taxes, and interest of 0.About Regenicin Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Regenicin. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Regenicin based exclusively on its fundamental and basic technical indicators. By analyzing Regenicin's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Regenicin's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regenicin. We calculate exposure to Regenicin's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Regenicin's related companies.Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
8 Steps to conduct Regenicin's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Regenicin's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Regenicin's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Regenicin's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Regenicin's revenue streams: Identify Regenicin's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Regenicin's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Regenicin's growth potential: Evaluate Regenicin's management, business model, and growth potential.
- Determine Regenicin's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Regenicin's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Regenicin Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 153.5 M | |
| Retained Earnings | -16 M |
Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.